Daratumumab as a Potential Treatment Option for Multiple Myeloma
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses daratumumab as a potential treatment option for patients with multiple myeloma.
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses daratumumab as a potential treatment option for patients with multiple myeloma.
Clinical Pearls:
- Daratumumab is a first-in-class CD38 monoclonal antibody
- Since CD38 is present on a number of other cell types, the first in-human dose-finding study proceeded cautiously with 0.005 mg/kg of the agent with dose escalation to 24 mg/kg
- At doses of 4 mg/kg or higher, the overall response rate, including minimal response, was over 60% and the rate of partial response or better was in the range of 40% to 45%, as defined as a 50% reduction in monoclonal protein
- Daratumumab was well tolerated but some infusion reactions were observed, specifically early on in the trial
- Daratumumab is now being studied in combination with other drugs, such as lenalidomide
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
